GLP Watchdog

MEDVi vs Mochi Health

MEDVi has an open FDA warning letter dated February 20, 2026. Mochi Health has none. No price lines up like for like. They share compounded semaglutide injection, but Mochi Health's $139 comes with plan terms the seller's page leaves unclear.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

MEDVi / Mochi Health

MEDVi logo

MEDVi

7.7/10

Mochi Health logo

Mochi Health

7.1/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$199/moCompounded semaglutide injection
$110/moFoundayo (orforglipron) pill
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit MEDVi
Visit Mochi Health

Neither MEDVi nor Mochi Health pays us. Links to them earn nothing. Scores: MEDVi 7.7, Mochi Health 7.1. How we are paid

What the record shows

  1. 01

    MEDVi has an open FDA warning letter dated February 20, 2026. Mochi Health has none.

  2. 02

    MEDVi names three pharmacies, all 503A. Mochi Health names no compounding pharmacy in our record.

  3. 03

    No price lines up like for like. They share compounded semaglutide injection, but Mochi Health's $139 comes with plan terms the seller's page leaves unclear.

  4. 04

    Only Mochi Health lists a price for compounded tirzepatide injection, brand-name semaglutide pen and brand-name tirzepatide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

MEDVi

Mochi Health

Compounded semaglutide injection

$199/mo

$2,388 a year

$139/mo

plan terms unclear; not compared

Compounded tirzepatide injection
Not sold or not priced

$169/mo

plan terms unclear; not compared

Brand-name semaglutide pen
Not sold or not priced

$199/mo

medication only, membership extra; not compared

Brand-name tirzepatide pen
Not sold or not priced

$299/mo

medication only, membership extra; not compared

Compounded oral semaglutide
Not sold or not priced

$141/mo

$1,692 a year

Brand-name semaglutide pill
Not sold or not priced

$149/mo

medication only, membership extra; not compared

Foundayo (orforglipron) pill
Not sold or not priced

$110/mo

$1,320 a year

Price includes
Medication, clinician visits, shipping, coaching
Clinician visits, coaching
Billed separately
Not stated
Medication
Cancel any time
Yes, stated
Yes, stated
Minimum term
None; billed monthly
None on the monthly plan; 3, 6 and 12-month memberships are prepaid
Refunds
Full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed
No refunds for partly used periods; medication is not refundable once sent to the pharmacy
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. MEDVi: October 25, 2026. Mochi Health: October 31, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for MEDVi

7.7/10
  • Names its compounding pharmacy
  • Open FDA warning letter, February 20, 2026
Visit MEDVi

The case for Mochi Health

7.1/10
  • No FDA warning letter on record
  • Sells compounded tirzepatide injection and brand-name semaglutide pen, which MEDVi does not price
  • Names no compounding pharmacy
  • Price leaves out medication
Visit Mochi Health

Scores

MEDVi 7.7 · Mochi Health 7.1 out of 10. Six weighted parts.

Value25%

5.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
7.5

Trust & Safety15%

6.0A
vs
B
8.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

8.5A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

MEDVi vs Mochi Health: questions

MEDVi has an open FDA warning letter dated February 20, 2026. Mochi Health has none. Letters are matched to a seller by company, domain and address, never by a similar name.
MEDVi names three pharmacies, all 503A. Mochi Health names no compounding pharmacy in our record. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
No price lines up like for like. They share compounded semaglutide injection, but Mochi Health's $139 comes with plan terms the seller's page leaves unclear. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
MEDVi states you can cancel at any time; refunds: full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed. Mochi Health states you can cancel at any time; refunds: no refunds for partly used periods; medication is not refundable once sent to the pharmacy.
Neither MEDVi nor Mochi Health pays us. Links to them earn nothing. Scores: MEDVi 7.7, Mochi Health 7.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks